Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma

Claudio Cerchione, Nour Alassi, Davide Nappi, Chiara Servili, Emanuela Scarpi, Delia Cangini, Sonia Ronconi, Michela Ceccolini, Matteo Paganelli, Luigi Coppola, Giacomo Feliciani, Alice Rossi, Fabiana Mammoli, Nicola Normanno, Gerardo Musuraca, Giorgia Simonetti, Giovanni Martinelli, Matteo Marchesini

Blood (2024) 144 (Supplement 1): 6838.

https://doi.org/10.1182/blood-2024-203211

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Blood (2024) 144 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2024-200012

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Impact-AML: A European Project for Optimizing Treatment and Assessing Quality of Life in Relapsed/Refractory Acute Myeloid Leukemia Patients

Antonio Maturo, Elisa Castellaccio, Veronica Moretti, Samantha Nier, Giovanni Martinelli, Giovanni Marconi, Gerardo Musuraca, Simone Adelsbach, Martina Vittoria Minguzzi, Maria Belles Esteller

Blood (2024) 144 (Supplement 1): 7651.

https://doi.org/10.1182/blood-2024-206970

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Lori A. Leslie, Chan Y. Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, Juraj Duras, Joost S.P. Vermaat, Gerardo Musuraca, Kojo Osei-Bonsu, Yi Hao, Kimberly G. Archer, Monica Wielgos-Bonvallet, Ali Rana, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2024-199652

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Claudio Cerchione, Davide Bezzi, Davide Nappi, Matteo Marchesini, Andrea Prochowski Iamurri, Paola Caroli, Arrigo Cattabriga, Delia Cangini, Giacomo Feliciani, Emiliano Loi, Federica Matteucci, Domenico Barone, Sonia Ronconi, Michela Ceccolini, Gerardo Musuraca, Nicola Normanno, Giovanni Martinelli, Alice Rossi

Blood (2024) 144 (Supplement 1): 3326.

https://doi.org/10.1182/blood-2024-211380

Published: 2024

Journal Articles

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 1580.

https://doi.org/10.1182/blood-2024-201391

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2023-182536

Published: 2023

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Blood (2023) 142 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2023-180333

Published: 2023

Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada

Blood (2023) 142 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2023-180935

Published: 2023

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Laura Nanni, Gerardo Musuraca, Alice Morigi, Vittorio Stefoni, Monica Barone, Gabriele Conti, Marco Fabbrini, Silvia Turroni, Alessandro Broccoli, Lisa Argnani, Patrizia Brigidi, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 4961–4963.

https://doi.org/10.1182/blood-2022-158175

Published: 2022

NARROW

Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Impact-AML: A European Project for Optimizing Treatment and Assessing Quality of Life in Relapsed/Refractory Acute Myeloid Leukemia Patients

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Multiple Myeloma and Smoldering Myeloma: Prospective Evaluation of 3 T Whole Body MRI and 18F-FDG PET/CT and Their Impact on Clinical Management

Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only